GlaxoSmithKline, Gilead HIV Combos Clear FDA
Executive Summary
GlaxoSmithKline will use a 60-day supply voucher program to help establish a patient base for its HIV-1 lamivudine/abacavir fixed-dose combination treatment Epzicom
You may also be interested in...
FDA Guidance On Combo HIV Products Will Allow Reviews In Six Weeks
FDA is setting a goal of reviewing fixed-dose combinations of HIV drugs in six weeks as part of the Bush Administration's $15 bil. Emergency Plan for AIDS Relief
Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life
Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011